KIR2DL4: A Potential Drug Target and Biomarker (G3805)

Target Name: KIR2DL4

NCBI ID: G3805

KIR2DL4

KIR2DL4: A Potential Drug Target and Biomarker

Immunology is a vital field of study that has revolutionized our understanding of the immune system. One of the key components of the immune response is the activation and proliferation of natural killer (NK) cells. These cells play a crucial role in fighting off infections and cancer cells, and their activity is critical for maintaining the balance of the immune system. One of the proteins that has been identified as a potential drug target in the NK cell system is KIR2DL4.

KIR2DL4 is a protein that is expressed in various tissues and cells, including the liver, spleen, and peripheral blood cells. It is a member of the immunoglobulin (Ig) family and has two Ig domains, as well as a long cytoplasmic tail. Transcript Variants of this gene have been identified, and some of them have been shown to be involved in the regulation of cellular processes such as cell adhesion, migration, and apoptosis.

One of the most interesting aspects of KIR2DL4 is its potential as a drug target. The NK cells are known for their ability to recognize and destroy infected or abnormal cells, making them an attractive target for cancer and other diseases. KIR2DL4 has been shown to be involved in the regulation of NK cell function, and it is possible that targeting this protein may be a promising strategy for the treatment of certain diseases.

One of the potential mechanisms by which KIR2DL4 may be involved in the immune response is its role in the regulation of NK cell death. NK cells are known for their ability to recognize and destroy infected or abnormal cells, but their own survival is often regulated by factors such as exposure to radiation or chemotherapy. KIR2DL4 has been shown to play a role in the regulation of NK cell apoptosis, which may be a critical mechanism by which the immune system eliminates infected or abnormal cells.

Another potential mechanism by which KIR2DL4 may be involved in the immune response is its role in the regulation of NK cell activation. NK cells are known for their ability to recognize and destroy infected or abnormal cells, but they must be activated in order to initiate an immune response. KIR2DL4 has been shown to play a role in the regulation of NK cell activation, and targeting this protein may be a promising strategy for the treatment of certain diseases.

In addition to its potential role in the regulation of NK cell function, KIR2DL4 has also been shown to be involved in the regulation of cellular processes such as cell adhesion and migration. These processes are important for the development and maintenance of tissues and organs, and may be critical for the development of certain diseases.

Overall, KIR2DL4 is a protein that has significant potential as a drug target in the NK cell system. Its role in the regulation of NK cell function, as well as its involvement in the regulation of cell adhesion and migration, make it an attractive target for the development of potential therapies for a variety of diseases. Further research is needed to fully understand the mechanisms by which KIR2DL4 functions, and to determine the best way to target this protein in order to develop effective therapies.

Protein Name: Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Long Cytoplasmic Tail 4

Functions: Receptor for non-classical major histocompatibility class Ib HLA-G molecules. Recognizes HLA-G in complex with B2M/beta-2 microglobulin and a nonamer self-peptide (peptide-bound HLA-G-B2M). In decidual NK cells, binds peptide-bound HLA-G-B2M complex and triggers NK cell senescence-associated secretory phenotype as a molecular switch to promote vascular remodeling and fetal growth in early pregnancy (PubMed:23184984, PubMed:29262349, PubMed:16366734). May play a role in balancing tolerance and antiviral-immunity at maternal-fetal interface by keeping in check the effector functions of NK, CD8+ T cells and B cells (PubMed:10190900, PubMed:16366734). Upon interaction with peptide-bound HLA-G-B2M, initiates signaling from the endosomal compartment leading to downstream activation of PRKDC-XRCC5 and AKT1, and ultimately triggering NF-kappa-B-dependent pro-inflammatory response (PubMed:20179272)

The "KIR2DL4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KIR2DL4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets